The accuracy of MRI, endorectal ultrasonography, and computed tomography in predicting the response of locally advanced rectal cancer after preoperative therapy: A metaanalysis

Surgery ◽  
2016 ◽  
Vol 159 (3) ◽  
pp. 688-699 ◽  
Author(s):  
Ellen A. de Jong ◽  
Josianne C.E.M. ten Berge ◽  
Roy S. Dwarkasing ◽  
Anton P. Rijkers ◽  
Casper H.J. van Eijck
2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 3543-3543
Author(s):  
B. Farnault ◽  
L. Moureau-Zabotto ◽  
C. de Chaisemartin ◽  
M. Giovannini ◽  
G. Monges ◽  
...  

2021 ◽  
Author(s):  
Yong Wang ◽  
Dongyan Liu ◽  
Lisha Peng ◽  
Feng Wang ◽  
Rongqing Li

Abstract Objective: To investigate whether the locally advanced rectal cancer patients who got a pathological complete response after neo-adjuvant chemoradiotherapy have a better survival. Methods: From January 1 2014 to January 1 2018, the clinical information of locally advanced rectal cancer patients who underwent neo-adjuvant chemoradiotherapy were collected for a retrospective analysis. Then a telephone follow-up visit was done to get the patients’ survival information of progression-free survival and overall survival. At last the information was analyzed by Kaplan-Meier analysis, log-rank test and cox-regression analysis. Results: The clinical information of 246 locally advanced rectal cancer patients were collected and analyzed, which shows that the PCR rate after chemoradiotherapy was 20.3% in these patients. There were correlations between pathological grade(grade III-IV Vs. I-II, P=0.001), CRM invasion(positive Vs. negative, P=0.001), clinical T stage(T4 Vs. T1-3, P=0.000), PCR status(PCR Vs. Non-PCR, P=0.027), downstage after preoperative therapy(yes Vs. not, P=0.009) and PFS. Similarly, age(≤60 Vs. >60, P=0.000), pathological grade(grade III-IV Vs. I-II, P=0.016), EMVI status(positive Vs. negative, P=0.005), CRM invasion(positive Vs. negative, P=0.000), clinical T stage(T4 Vs. T1-3, P=0.000), clinical N stage(N0-1 Vs. N2, P=0.013), PCR status(PCR Vs. Non-PCR, P=0.010), downstage after preoperative therapy(yes Vs. not, P=0.002) were associated with the OS. After the Cox-regression analyses, the responses after preoperative therapy or T4 tumors were identified as the prognostic factors that affected PFS and OS. Conclusions: The PCR rate after chemoradiotherapy was 20.3% in locally advanced rectal patients. Stage T1-3, better response after chemoradiotherapy tumors (PCR or downstage) might have a better survival outcome.


2018 ◽  
Vol 36 (6) ◽  
pp. 495-501 ◽  
Author(s):  
George Ramsay ◽  
Duncan T. Ritchie ◽  
Craig MacKay ◽  
Craig Parnaby ◽  
Graeme Murray ◽  
...  

Background: Outcomes in locally advanced rectal cancer are improved by neoadjuvant therapy followed by surgical resection. Some patients respond completely to preoperative treatment. Therefore, predicting the pathological response to preoperative therapy is of clinical importance. Accurate prediction would allow for tailored approaches to neoadjuvant therapy. Methods: All patients undergoing resection of rectal adenocarcinoma after neoadjuvant therapy between 2006 and 2015 were included in this cohort study. Patients were identified from a prospectively collected database and data were supplemented retrospectively with full blood count at diagnosis. Specimens resected following neoadjuvant therapy were graded according to pathological response. Follow-up data was obtained from the national registry. The primary outcome was complete pathological response. Results: Of 330 patients, 71 (21.5%) responded completely to preoperative therapy. Median age was 66 and 65% were male (n = 215). White cell count (WCC) was the most predictive marker, for predicting pCR; area under the curve (AUC) 0.666. This was higher than neutrophil/platelet ratio (AUC 0.652) or neutrophil/lymphocyte ratios (AUC = 0.437). Kaplan-Meier survival analysis showed those patients with WCC > 8 had poorer survival than those with WCC < 8 (p = 0.009). Conclusion: Routinely collected haematology samples at the point of diagnosis can assist in predicting for complete response to neoadjuvant therapy. Although novel biomarkers will have a greater predictive value, this clinically available value test could help to assist in risk stratification of patients using routinely collected laboratory tests.


Sign in / Sign up

Export Citation Format

Share Document